ECKERT & ZIEGLER SE
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Quarter Results
???????Eckert & Ziegler: Record Income Due to Sale of Division and Strong Core Business
2021-05-17 / 07:45
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Berlin, 17 May 2021. One-off effects from the deconsolidation of the tumor irradiation business, a waning of the Corona
slump, and continued strong demand in particular for pharmaceutical radioisotopes more than doubled net profit at
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700; TecDAX) in the first quarter of 2021. With sales
revenues of 44 million EUR (PY: 44), the Berlin-based technology company posted a net profit of 13.8 million EUR, 8.8
million EUR more than in the same period of the previous year
6.8 million EUR of the quarterly profit were booked as a one-off in the Medical Segment due to the deconsolidation of
the tumor irradiation business. Another 4.9 mm EUR of net income (36% more than last year) was generated in this
segment in particular through stronger sales of pharmaceutical radioisotopes, but also of laboratory devices and
nuclear production equipment. The performance in these sub-segments more than compensated a weak start in the project
business (services for companies). The Industrial segment returned to pre-Corona profitability and closed the quarter
with a net income of EUR 2.5 million. The holding, the group's third segment, where pre-clinical development expenses
are booked, showed a loss of 0.4 mm EUR.
Although almost half (48%) of the 2021 annual income goal of EUR 29 million was already achieved in the first quarter,
the Executive Board for now sticks to the guidance published in March due to the ongoing pandemic, the travel
restrictions that continue to hamper business, and the extended delivery times for preliminary products, for example in
plant construction.
The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz121e.pdf
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with her 800 employees is a leading specialist for isotope-related
components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the
radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler
shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com
=----------------------------------------------------------------------------------------------------------------------
2021-05-17 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1196935
End of News DGAP News Service
=------------ 1196935 2021-05-17
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1196935&application_name=news(END) Dow Jones Newswires
May 17, 2021 01:45 ET (05:45 GMT)
